72 related articles for article (PubMed ID: 17694580)
1. Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.
Bala MV; Zarkin GA; Mauskopf J
Health Econ; 2008 Mar; 17(3):435-40. PubMed ID: 17694580
[TBL] [Abstract][Full Text] [Related]
2. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
3. Health technology assessment in the cost-disutility plane.
Eckermann S; Briggs A; Willan AR
Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hearing aids in the hearing-impaired elderly: a probabilistic approach.
Chao TK; Chen TH
Otol Neurotol; 2008 Sep; 29(6):776-83. PubMed ID: 18725859
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness acceptability curves--caveats quantified.
Jakubczyk M; Kamiński B
Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
[TBL] [Abstract][Full Text] [Related]
6. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
7. Valuing reduced antibiotic use for pediatric acute otitis media.
Meropol SB
Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
Oba Y
Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
[TBL] [Abstract][Full Text] [Related]
9. Expected value of information and decision making in HTA.
Eckermann S; Willan AR
Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
[TBL] [Abstract][Full Text] [Related]
10. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
[TBL] [Abstract][Full Text] [Related]
11. The impact of using different imputation methods for missing quality of life scores on the estimation of the cost-effectiveness of lung-volume-reduction surgery.
Blough DK; Ramsey S; Sullivan SD; Yusen R;
Health Econ; 2009 Jan; 18(1):91-101. PubMed ID: 18435426
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
13. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Negrín MA; Vázquez-Polo FJ
J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian model averaging approach for cost-effectiveness analyses.
Conigliani C; Tancredi A
Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
[TBL] [Abstract][Full Text] [Related]
15. A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach.
Ramsey SD; Blough DK; Sullivan SD
Med Care; 2008 May; 46(5):542-8. PubMed ID: 18438203
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
18. Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management.
Das A; Ngamruengphong S; Nagendra S; Chak A
Gastrointest Endosc; 2009 Oct; 70(4):690-699.e6. PubMed ID: 19647240
[TBL] [Abstract][Full Text] [Related]
19. Decision modelling of economic evaluation of intervention programme of breast cancer.
Chang JC; Chen TH; Duffy SW; Yen AM; Chen SL
J Eval Clin Pract; 2010 Dec; 16(6):1282-8. PubMed ID: 20831661
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model.
Bounthavong M; Hsu DI; Okamoto MP
Int J Clin Pract; 2009 Mar; 63(3):376-86. PubMed ID: 19222624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]